Part-Time

Quality Assurance Associate

Karius

Karius

201-500 employees

Non-invasive liquid biopsy for infectious pathogens

Compensation Overview

$41.47 - $62.21/hr

Redwood City, CA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Machine Learning
Quality Assurance (QA)

Get referred to Karius

See people who can refer or advise you

Requirements
  • Excellent organization skills allowing the coordination of multi-faceted quality assurance activities.
  • Strong attention to detail, organization, and teamwork skills.
  • Ability to prioritize multiple tasks concurrently and meet deadlines.
  • Excellent writing and digital literacy.
  • Ability to proactively communicate in a consistent, clear and open manner.
  • Flexible, adaptive and comfortable in a rapidly evolving biotechnology start-up environment.
  • Strong knowledge of Microsoft Office applications.
  • Excellent written and verbal communication skills.
  • Knowledge of quality management system standards.
  • Strong analytical and problem-solving skills.
  • The role requires extended periods of sitting or standing, vision to monitor, and tolerance for moderate noise levels.
  • The role may involve exposure to hazardous materials, blood specimens, and instruments, and may require lifting up to 25 pounds.
Responsibilities
  • Support and administer the document control system, including revision and maintenance of laboratory documents, to ensure compliance with Clinical Laboratory Improvement Amendments regulations.
  • Ensure that all documents are current, properly stored, and accessible to relevant personnel.
  • Assist with personnel onboarding, including introduction to the controlled document system and personnel binders, and track training, competency, and continuing education status.
  • Prepare documentation of training and competency records for review.
  • Maintain standard operating procedures, work instructions, and quality records for quality assurance systems.
  • Review and improve existing quality procedure workflows and identify areas for efficiency and compliance improvements.
  • Administer training materials and modules for good laboratory practice activities.
  • Support internal and external regulatory audits as required.
  • Help maintain quality records in a state of inspection readiness.
  • Support continuous improvement initiatives involving quality procedure workflows and aspects of the quality management system.
  • Provide administrative support for the incident management system.
  • Support documentation needs of core teams, including routing validation packages and laboratory change control forms.
Desired Qualifications
  • One to two years of pertinent industry experience.
  • Experience with deviations, laboratory investigations, out-of-specification events, and corrective and preventive actions.
  • A Bachelor of Science degree in a biological science or similar field of study.

Karius provides rapid, non-invasive infectious-disease diagnostics using the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. The test analyzes microbial cell-free DNA circulating in the bloodstream, using advanced genomics and artificial intelligence to identify pathogens. It operates on real-time genomic data and a constantly updated reference database, enabling clinicians to diagnose infections without multiple invasive tests. Unlike traditional methods, Karius combines a broad pathogen panel with machine-learning analysis to deliver faster results and reduce unnecessary procedures. The company's goal is to help healthcare providers diagnose infections quickly, improve patient outcomes, and reduce healthcare costs by offering a faster, less invasive diagnostic option.

Company Size

201-500

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Get referred to Karius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mayo Clinic Laboratories collaboration expands ordering access and 24-hour reporting in April 2026.
  • BARDA contract in August 2024 supports pathogen-agnostic detection and public-sector validation.
  • Revelio showed 199 employees in March 2026, signaling continued hiring despite a 2% year-over-year dip.

What critics are saying

  • Karius still lacks FDA marketing authorization, leaving reimbursement and adoption dependent on LDT status.
  • Plasma mcfDNA competitors like Mayo metagenomics compress differentiation and pricing power in 2026.
  • If clinical utility stalls, Karius becomes a premium testing niche before 2027.

What makes Karius unique

  • Karius Spectrum and Focus | BAL reach Mayo Clinic Laboratories on April 23, 2026.
  • FDA Breakthrough Device designation on May 16, 2024 validates Karius's lung-infection strategy.
  • March 2026 Lancet Microbe study strengthens Karius's blood-draw metagenomic credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

0%
Business Wire
May 16th, 2024
Karius Test® Receives Fda Breakthrough Device Designation To Aid In The Diagnosis Of Infectious Disease

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a leader in genomic diagnostics for infectious diseases, announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” stated Brad Perkins, M.D., Chief Medical Officer of Karius. “As noted in the American Thoracic Society (ATS) Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria,1 lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.”. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these innovative medical devices

Forbes
May 8th, 2024
Innovationrx: Deepmind Unveils Its New Protein-Folding Ai Model Alphafold 3

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. A protein folding prediction in response to a small molecule generated by AlphaFold 3.Isomorphic LabsToday, Deepmind announced the launch of AlphaFold 3, the next generation of its AI software for structural biology, which has enabled thousands of researchers to predict the complicated chemical interactions involved with proteins. One major difference in the new iteration of the program: instead of just predicting protein folding, it predicts the interactions of other biological molecules as well including DNA, RNA and small molecules. The company published the accuracy of its predictions in the journal Nature.In addition to the new capabilities–which even includes the ability to make predictions based on epigenetic changes to DNA–the company has also launched AlphaFold Server, a web service that enables researchers to generate biochemical models without having to install the system itself from open source code, as was the case with previous iterations. Something else new is that AlphaFold now works with diffusion models – which are popularly known for being used by AI systems that generate images from text prompts – in place of some of its previous structural models.“The response to AlphaFold 2 was more than I could have ever imagined in terms of the kind of creativity and what the research community has done with it,” Deepmind research director John Jumper said at a press briefing

Citybiz
May 3rd, 2024
Karius Secures $100M in Series C

Karius, Inc., a genomic diagnostics company, has raised $100 million in a Series C funding round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare. The funds will be used to expand the reach of the Karius Test®, which detects over 1,000 pathogens from a single blood sample, beyond 400 U.S. hospitals. The company also added three new board members, including Alex Morgan from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth from 5AM Ventures.

RamaOnHealthcare
May 2nd, 2024
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Karius secures $100M to expand non-invasive pathogen blood Test.

Business Wire
May 2nd, 2024
Karius Secures $100M for Genomic Diagnostics Expansion

Karius, Inc. has raised $100M in Series C funding, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from Seventure Partners and others. The funds will expand the reach of the Karius Test®, a genomic diagnostic test for infectious diseases, beyond 400 U.S. hospitals. The investment also supports research into microbial cell-free DNA technology. Additionally, Karius announced three new board members.